143 related articles for article (PubMed ID: 18157598)
1. [TRUST study: general practice relevant data on erlotinib in NSCLC].
Knabl A
Wien Med Wochenschr; 2007; 157(21-22):579-80. PubMed ID: 18157598
[No Abstract] [Full Text] [Related]
2. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
[TBL] [Abstract][Full Text] [Related]
3. [Erlotinib in the treatment of NSCLC: current and novel prospects from the ASCO 2006].
Longo F; Giovanni M
Tumori; 2006; 92(5):suppl 13-22. PubMed ID: 17168450
[No Abstract] [Full Text] [Related]
4. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
5. Network meta-analysis: importance of appropriate trial selection.
Edwards SJ; Borrill J
Value Health; 2010 Aug; 13(5):681-2; author reply 683. PubMed ID: 20345543
[No Abstract] [Full Text] [Related]
6. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
7. [Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
Krankenpfl J; 2004; 42(5-6):158. PubMed ID: 15527222
[No Abstract] [Full Text] [Related]
8. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
9. Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal?
Eberhardt W
J Thorac Oncol; 2010 Oct; 5(10):1495-7. PubMed ID: 20871257
[No Abstract] [Full Text] [Related]
10. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
PĂ©rol M
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
[No Abstract] [Full Text] [Related]
11. Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
Paz-Ares L
Lancet Oncol; 2012 Mar; 13(3):225-7. PubMed ID: 22277836
[No Abstract] [Full Text] [Related]
12. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Giaccone G; Gallegos Ruiz M; Le Chevalier T; Thatcher N; Smit E; Rodriguez JA; Janne P; Oulid-Aissa D; Soria JC
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6049-55. PubMed ID: 17062680
[TBL] [Abstract][Full Text] [Related]
13. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
14. Management of non-small cell lung cancer: focus on erlotinib. Foreword.
Cappuzzo F
Drugs; 2012 Jun; 72 Suppl 1():1-2. PubMed ID: 22712791
[No Abstract] [Full Text] [Related]
15. Erlotinib in lung cancer.
Takano T; Ohe Y
N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240472
[No Abstract] [Full Text] [Related]
16. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
17. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Dillon B; Naidoo B; Knight H; Clark P
Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
[No Abstract] [Full Text] [Related]
18. [A new medication for lung cancer].
Krankenpfl J; 2005; 43(7-10):227. PubMed ID: 16515296
[No Abstract] [Full Text] [Related]
19. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Lee VW; Schwander B; Lee VH
Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]